Ezetimibe plus moderate-intensity statin versus high-intensity statin

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Atherosclerotic cardiovascular disease (ASCVD) requires effective lipid-lowering therapies.
• High-intensity statins are standard, but side effects can limit use.
• Combination therapy offers an alternative approach.

Purpose of the Study:

• To compare the long-term efficacy and safety of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy.
• To assess non-inferiority of the combination therapy in ASCVD patients.

Main Methods:

• A randomized, open-label, non-inferiority trial (RACING trial).
• Involved patients with established atherosclerotic cardiovascular disease.
• Compared moderate-intensity statin with ezetimibe versus high-intensity statin monotherapy.

Main Results:

• The combination therapy was non-inferior to high-intensity statin monotherapy in terms of major adverse cardiovascular events.
• Both treatment strategies demonstrated comparable safety profiles.
• Long-term efficacy was maintained in the combination therapy group.

Conclusions:

• Moderate-intensity statin with ezetimibe is a viable and effective alternative to high-intensity statin monotherapy for ASCVD.
• This combination offers a potentially better-tolerated option for lipid management.
• Findings support personalized treatment approaches in cardiovascular disease prevention.